Ercalcitriol(Ercalcitriol) - 药物靶点：VDR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

VDR

作用机制

VDR激动剂(维生素D受体激动剂)

治疗领域

内分泌与代谢疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

继发性甲状旁腺功能亢进症终末期肾脏病

原研机构

OPKO Health, Inc.

在研机构-

非在研机构

OPKO IP Holdings II, Inc.

OPKO Health, Inc.

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C28H44O3

InChIKeyZGLHBRQAEXKACO-XJRQOBMKSA-N

CAS号60133-18-8

关联

1

项与 Ercalcitriol 相关的临床试验

NCT00792857 / Completed临床1期

Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis

This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths. This study will also investigate the levels of CTAP201 in the body over time and determine the safety of CTAP201.

开始日期2008-11-01

申办/合作机构

OPKO IP Holdings II, Inc.

100 项与 Ercalcitriol 相关的临床结果

登录后查看更多信息

100 项与 Ercalcitriol 相关的转化医学

登录后查看更多信息

100 项与 Ercalcitriol 相关的专利（医药）

登录后查看更多信息

1

项与 Ercalcitriol 相关的文献（医药）

1990-10-01·Clinica Chimica Acta3区 · 医学

A sensitive radioimmunoassay using a monoclonal antibody that is equipotent for ercalcitriol and calcitriol (1,25-dihydroxy vitamin D2 and D3)

3区 · 医学

Article

作者: Berry, Jacqueline L. ; Cundall, J. Paul ; Still, Pamela E. ; White, Anne ; Mawer, E. Barbara

A monoclonal antibody has been used in a sensitive radioimmunoassay that measures 1,25-dihydroxyvitamin D2 (ercalcitriol) and 1,25-dihydroxyvitamin D3 (calcitriol) with equal potency. This important characteristic has not been reported for any other radioimmunoassay for 1,25-dihydroxyvitamin D. The two forms can be assayed in human serum together or individually after HPLC separation. Sample preparation entails acetonitrile extraction followed by C18-Sep-pak chromatography and HPLC. The assay measures 98% of added analyte, and achieves inter- and intra-assay coefficients of variation of 10.7% at 34 pg/ml and 7.8% at 81 pg/ml respectively. The limit of detection is 1.25 pg/tube and 50% displacement of bound ligand is achieved at 14 pg/tube. The reference interval is 20-50 pg/ml, mean 35. The correlation between results from the monoclonal radioimmunoassay and an established polyclonal antibody method was r = 0.98, slope 0.99. The assay has particular application in patients treated with vitamin D2 since 1,25-dihydroxyvitamin D2 can now be measured accurately in the presence of 1,25-dihydroxyvitamin D3.

100 项与 Ercalcitriol 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
终末期肾脏病	临床1期	美国	OPKO IP Holdings II, Inc.	2008-11-01
继发性甲状旁腺功能亢进症	临床1期	-	OPKO Health, Inc.	-
继发性甲状旁腺功能亢进症	临床1期	-	OPKO Health, Inc.	-